JAK inhibitor ameliorate autoimmunity and nephritis in lupus prone mice

ABSTRACT: We previously reported that JAK/STAT pathway-mediated regulation of IRF-related genes may have an important role in the disease activity of SLE through analyzing the difference of gene expression in peripheral blood CD3+ T cells obtained from SLE patients. Recently pan-JAK inhibitor (JAKi) tofacitinib (TOFA) were developed and successfully applied to patients with rheumatoid arthritis. Therefore, the application possibility of TOFA was investigated for the new therapeutic strategy of SLE. Anti-dsDNA antibody and proteinuria were decreased and glomerulo/interstitial nephritis were ameliorated in any TOFA administered SLE mice. In splenic CD4+ T cell analysis, naïve cells significantly increased and effector/memory cells decreased. TOFA with dexamethasone (DEXA) therapy showed tendency

ORGANISM(S): Mus musculus

SUBMITTER: Keigo Ikeda 

PROVIDER: E-GEOD-78825 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress